Home FDA labels 6ea27755-e1d5-47f1-b6b6-54868f628fca FDA label 6ea27755-e1d5-47f1-b6b6-54868f628fca openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID 4505de2a-ef6f-4bb7-9845-1228afbe0a0e
SPL ID 6ea27755-e1d5-47f1-b6b6-54868f628fca
Version 2
Effective date 2025-12-03
Source export date 2026-08-08
Source partition 6
Source file https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-08-08/1742e81476d3d6cada20c9e3894391dc6e407b1d0da716d0da13f6f74451bfd1/drug-label-0006-of-0014.json.zip
Source manifest SHA-256 b39f3b00ad50d2e1b32aaf429248c6081e8799b35bce715b4fccb8cfa1ac4546
Import run 20260810T161303Z
Imported at 2026-08-10 16:57:07 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Warnings cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings and cautions 5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions, Including Hypotension, Wheezing, Shortness of Breath and Bronchospasm: Observe patients during and after the infusion; immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment. Acetylcysteine injection infusion may be carefully restarted after treatment of hypersensitivity has been initiated. ( 5.1 ) • Fluid Overload : Total volume administered should be reduced for patients weighing less than 40 kg and for those requiring fluid restriction. ( 5.2 ) 5.1 Hypersensitivity Reactions Serious acute hypersensitivity reactions during acetylcysteine administration including rash, hypotension, wheezing, and/or shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [see Adverse Reactions ( 6.1 )] . If a severe hypersensitivity reaction occurs, immediately stop the infusion of acetylcysteine injection and initiate appropriate treatment. One patient with asthma developed bronchospasm and died after intravenous administration of acetylcysteine injection should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during initiation of acetylcysteine injection therapy and throughout acetylcysteine injection therapy. Acute flushing and erythema of the skin may occur in patients receiving acetylcysteine intravenously. These reactions usually occur 30 to 60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion of acetylcysteine. If a reaction to acetylcysteine involves more than simply flushing and erythema of the skin, it should be treated as a hypersensitivity reaction. Management of less severe hypersensitivity reactions should be based upon the severity of the reaction and include temporary interruption of the infusion and/or administration of antihistaminic drugs. The acetylcysteine injection infusion may be carefully restarted after treatment of the hypersensitivity symptoms has been initiated; however, if the hypersensitivity reaction returns upon re-initiation of treatment or increases in severity, acetylcysteine injection should be discontinued and alternative patient management should be considered. 5.2 Fluid Overload The total volume of acetylcysteine injection administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed [see Dosage and Administration ( 2 )] . If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia, seizure and death. Intravenous administration of acetylcysteine injection can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload, use the recommended dilution shown in Tables 2, 3 and 4 [see Dosage and Administration ( 2.4 )].
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 4 matching rows.
adverse reactions 6 ADVERSE REACTIONS Most common adverse reactions (>2%) are rash, urticaria/facial flushing and pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Exela Pharma Sciences, LLC at 1-888-451-4321 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the literature the most frequently reported adverse reactions attributed to intravenous acetylcysteine administration were rash, urticaria and pruritus. The frequency of adverse reactions has been reported to be between 0.2% and 21%, and they most commonly occur during the initial loading dose of acetylcysteine. Loading Dose/Infusion Rate Study In a randomized, open-label, multi-center clinical study conducted in Australia in patients with acetaminophen poisoning, the rates of hypersensitivity reactions between a 15-minute and 60-minute intravenous infusion for the150 mg/kg loading dose of acetylcysteine were compared. The incidence of drug-related adverse reactions occurring within the first 2 hours following acetylcysteine administration is presented in Table 5. Overall, 17% of patients developed an acute hypersensitivity reaction (18% in the 15-minute infusion group; 14% in the 60-minute infusion group) [see Warnings and Precautions ( 5.1 ), Clinical Studies ( 14 )] . Table 1. Incidence of Drug-Related Adverse Reactions Occurring Within the First 2 Hours Following Study Drug Administration by Preferred Term: Loading Dose/Infusion Rate Study Treatment Group 15-mins 60-mins Number of Patients n=109 n=71 Cardiac disorders 5 (5%) 2 (3%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Tachycardia NOS 4 (4%) 1 (1%) 2 (3%) Gastrointestinal disorders 16 (15%) 7 (10%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Nausea 1 (1%) 6 (6%) 1 (1%) 1 (1%) Vomiting NOS 2 (2%) 11 (10%) 2 (3%) 4 (6%) Immune System Disorders 20 (18%) 10 (14%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Hypersensitivity reaction 2 (2%) 6 (6%) 11 (10%) 1 (1%) 4 (6%) 5 (7%) 1 (1%) Respiratory, thoracic and mediastinal disorders 2 (2%) 2 (3%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Pharyngitis 1 (1%) Rhinorrhea 1 (1%) Rhonchi 1 (1%) Throat tightness 1 (1%) Skin & subcutaneous tissue disorders 6 (6%) 5 (7%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Pruritus 1 (1%) 2 (3%) Rash NOS 3 (3%) 2 (2%) 3 (4%) Vascular disorders 2 (2%) 3 (4%) Severity: Unkn Mild Moderate Severe Unkn Mild Moderate Severe Flushing 1 (1%) 1 (1%) 2 (3%) 1 (1%) Unkn = Unknown; NOS = not otherwise specified Safety Study A large multi-center study was performed in Canada where data were collected from patients who were treated with intravenous acetylcysteine for acetaminophen overdose between 1980 and 2005. This study evaluated 4709 adult cases and 1905 pediatric cases. The incidence of hypersensitivity reactions in adult (overall incidence 8%) and pediatric (overall incidence 10%) patients is presented in Tables 6 and 7. Table 2. Distribution of reported hypersensitivity reactions in adult patients receiving intravenous acetylcysteine Reaction Incidence (%) n=4709 Urticaria/Facial Flushing 6.1% Pruritus 4.3% Respiratory Symptoms* 1.9% Edema 1.6% Hypotension 0.1% Anaphylaxis 0.1% Table 3. Distribution of reported hypersensitivity reactions in pediatric patients receiving intravenous acetylcysteine Reaction Incidence (%) n=1905 Urticaria/Facial Flushing 7.6% Pruritus 4.1% Respiratory Symptoms* 2.2% Edema 1.2% Anaphylaxis 0.2% Hypotension 0.1% *Respiratory symptoms are defined as presence of any of the following: cough, wheezing, stridor, shortness of breath, chest tightness, respiratory distress, or bronchospasm.
adverse reactions table <table ID="_RefID0ERTAE" width="100%"><caption>Table 1. Incidence of Drug-Related Adverse Reactions Occurring Within the First 2 Hours Following Study Drug Administration by Preferred Term: Loading Dose/Infusion Rate Study</caption><col width="21%"/><col width="15%"/><col width="7%"/><col width="11%"/><col width="9%"/><col width="10%"/><col width="7%"/><col width="11%"/><col width="9%"/><tbody><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="middle"><paragraph><content styleCode="bold">Treatment Group </content></paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule Toprule " valign="middle"><paragraph><content styleCode="bold">15-mins </content></paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule Toprule " valign="middle"><paragraph><content styleCode="bold">60-mins</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Number of Patients </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>n=109 </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>n=71 </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Cardiac disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>5 (5%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Tachycardia NOS </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>4 (4%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Gastrointestinal disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>16 (15%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>7 (10%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="middle"><paragraph>Nausea </paragraph></td><td styleCode="Rrule Botrule " valign="middle"><list listType="unordered"><item><caption> </caption>1 (1%) </item></list></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>6 (6%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Vomiting NOS </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (2%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>11 (10%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>4 (6%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Immune System Disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>20 (18%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>10 (14%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Hypersensitivity reaction </paragraph></td><td styleCode="Rrule Botrule " valign="middle"><list listType="unordered"><item><caption> </caption> 2 (2%)</item></list></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>6 (6%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>11 (10%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td styleCode="Rrule Botrule " valign="middle"><paragraph>4 (6%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>5 (7%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Respiratory, thoracic and mediastinal disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (2%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="middle"><paragraph>Pharyngitis </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="middle"><paragraph>Rhinorrhea </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="middle"><paragraph>Rhonchi </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Throat tightness </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Skin & subcutaneous tissue disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>6 (6%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>5 (7%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="middle"><paragraph>Pruritus </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Rash NOS </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>3 (3%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (2%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>3 (4%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Vascular disorders </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (2%) </paragraph></td><td align="center" colspan="4" styleCode="Rrule Botrule " valign="middle"><paragraph>3 (4%) </paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="italics">Severity:</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Unkn</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Mild</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Moderate</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph><content styleCode="italics">Severe</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>Flushing </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>2 (3%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph>1 (1%) </paragraph></td><td align="center" styleCode="Rrule Botrule " valign="middle"><paragraph> </paragraph></td></tr><tr><td colspan="9" styleCode="Botrule " valign="top"><paragraph><content styleCode="italics">Unkn = Unknown; NOS = not otherwise specified </content></paragraph></td></tr></tbody></table>
adverse reactions table <table ID="_RefID0EMWAG" width="100%"><caption>Table 2. Distribution of reported hypersensitivity reactions in adult patients receiving intravenous acetylcysteine</caption><col width="50%"/><col width="50%"/><tbody><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Reaction</content></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Incidence (%) n=4709 </content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Urticaria/Facial Flushing </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>6.1%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pruritus </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>4.3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Respiratory Symptoms* </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1.9%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Edema </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1.6%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hypotension </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>0.1%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Anaphylaxis </paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>0.1%</paragraph></td></tr></tbody></table>
adverse reactions table <table ID="_RefID0EE2AG" width="100%"><caption>Table 3. Distribution of reported hypersensitivity reactions in pediatric patients receiving intravenous acetylcysteine</caption><col width="50%"/><col width="50%"/><tbody><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Reaction</content></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Incidence (%) n=1905</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Urticaria/Facial Flushing </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>7.6%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pruritus </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>4.1%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Respiratory Symptoms* </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>2.2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Edema </paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>1.2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Anaphylaxis</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>0.2%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="bottom"><paragraph>0.1%</paragraph></td></tr></tbody></table>